ReNeuron Group (ReNeuron Group) Debt-to-Equity : 0.14 (As of Sep. 2023)

View and export this data going back to 2006. Start your Free Trial

What is ReNeuron Group Debt-to-Equity?

ReNeuron Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.19 Mil. ReNeuron Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.23 Mil. ReNeuron Group's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $3.00 Mil. ReNeuron Group's debt to equity for the quarter that ended in Sep. 2023 was 0.14.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for ReNeuron Group's Debt-to-Equity or its related term are showing as below:

RNUGF' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03 Med: 0.06 Max: 0.14
Current: 0.14

During the past 13 years, the highest Debt-to-Equity Ratio of ReNeuron Group was 0.14. The lowest was 0.03. And the median was 0.06.

RNUGF's Debt-to-Equity is ranked better than
51.08% of 1069 companies
in the Biotechnology industry
Industry Median: 0.14 vs RNUGF: 0.14

ReNeuron Group Debt-to-Equity Historical Data

The historical data trend for ReNeuron Group's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ReNeuron Group Debt-to-Equity Chart

ReNeuron Group Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Debt-to-Equity

Get a 7-Day Free Trial

0.04

0.07

0.04

0.06

0.08

ReNeuron Group Semi-Annual Data
	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Debt-to-Equity	Get a 7-Day Free Trial															0.05	0.06	0.07	0.08	0.14

Competitive Comparison of ReNeuron Group's Debt-to-Equity

For the Biotechnology subindustry, ReNeuron Group's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ReNeuron Group's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ReNeuron Group's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where ReNeuron Group's Debt-to-Equity falls into.

ReNeuron Group Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

ReNeuron Group's Debt to Equity Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.186	+	0.325)	/	6.137
	=	0.08

ReNeuron Group's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.193	+	0.234)	/	2.996
	=	0.14

ReNeuron Group (OTCPK:RNUGF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

ReNeuron Group Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of ReNeuron Group's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

ReNeuron Group (ReNeuron Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ReNeuron Group PLC (OTCPK:RNUGF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

RENE.GB:UK RENE:UK RQE1:Germany

Address

Pencoed Business Park, Pencoed, Bridgend, GBR, CF35 5HY

Website

https://www.reneuron.com

ReNeuron Group PLC is engaged in the field of biotechnology. Its core activities include the research and clinical development of cell-based therapeutics. The company product pipeline includes the human retinal progenitor cell line (hRPC) and CTX neural cell line. It derives revenue from UK and U.S. The company is mainly focusing on the treatment of stroke disability, inherited retinal diseases, and cancer.